Abcam PLC ADR ABCM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABCM is a good fit for your portfolio.
News
-
Danaher Completes Acquisition of Abcam
-
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
-
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023
-
Shareholders of Abcam Approve Proposed Acquisition by Danaher
-
Leading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam
-
Leading Proxy Advisor, ISS, Recommends Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam
-
Independent Directors of Abcam Highlight Compelling Reasons for Shareholders to Support Proposed Sale to Danaher
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, HT, ABCM, ACER
Trading Information
- Previous Close Price
- $23.98
- Day Range
- $23.98–24.00
- 52-Week Range
- $12.48–25.32
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $5.52 Bil
- Volume/Avg
- 7.4 Mil / 5.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- 102.22
- Price/Sales
- 12.21
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,800
- Website
- https://www.abcam.com
Valuation
|
Metric
|
ABCM
|
|---|---|
Price/Earnings (Normalized) | 102.22 |
Price/Book Value | 6.08 |
Price/Sales | 12.21 |
Price/Cash Flow | 60.58 |
Price/Earnings
ABCM
Financial Strength
|
Metric
|
ABCM
|
|---|---|
Quick Ratio | 0.99 |
Current Ratio | 1.35 |
Interest Coverage | 0.93 |
Quick Ratio
ABCM
Profitability
|
Metric
|
ABCM
|
|---|---|
Return on Assets (Normalized) | 6.16% |
Return on Equity (Normalized) | 8.92% |
Return on Invested Capital (Normalized) | 7.46% |
Return on Assets
ABCM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nvtny | $445.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jllmgnj | $91.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dhqgnx | $91.1 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Pytpbx | $40.7 Bil | |
MRNA
| Moderna Inc | Dsrv | $30.7 Bil | |
ARGX
| argenx SE ADR | Fkhp | $27.7 Bil | |
BNTX
| BioNTech SE ADR | Rcddh | $24.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nbtmklx | $22.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hcvczd | $17.7 Bil | |
INCY
| Incyte Corp | Fcydchn | $12.4 Bil |